The Foundation for the National Institutes of Health (FNIH) https://fnih.org , and the National Heart, Lung, and Blood Institute (NHLBI) https://.nhlbi.nih.gov are launching a new partnership to investigate the syndrome of Heart Failure with Preserved Ejection Fraction (HFpEF).
Developing precision treatment strategies for HFpEF is more critical than ever, as the world’s population continues to live longer which is resulting in an increase in HFpEF cases. Utilizing cutting edge technologies, including digital measurements and AI analytic methods, the Accelerating Medicine Partnership® Heart Failure (AMPHF) Program is designed to find novel proteins or genes that could mitigate this disease when altered by therapeutics.
AMPHF, brings together the resources of eight partner organizations spanning the public and private sectors with a combined commitment totaling over $37 million. The FNIH will provide project management for the effort over the next five years.
Private partners include the American Society of Echocardiography, Bayer AG, Cytokinetics, Inc, Ionis Pharmaceuticals, Inc., Novartis AG, and Ultromics along with support provided by the American Heart Association.
“HFpEF is clearly a major cause of heart failure hospitalizations and diminishes the quality of life for older patients. Through AMPHF, we will harness valuable perspectives and expertise that collaborations can bring to biomedical research, which will pave the way for a more hopeful outlook,” said Dr. Julie Gerberding, CEO, FNIH.